What question did this study set out to answer?

This review aims to summarize and compare various tools used for assessing chemotherapy-induced peripheral neuropathy (CIPN).

January 10, 2026JNCI Cancer Spectrum0 citationsOpen Access

Assessment tools for Chemotherapy-Induced peripheral neuropathy: a narrative review of clinician, Patient-Reported, and objective measures

KCKaitlin Chen ЕАЕ. Г. Антонен MNMichelle B. Nadler

Key Result

Among 20 patient-reported outcome measures for chemotherapy-induced peripheral neuropathy, few have established minimum clinically important differences or validation in CIPN populations.

Key Points

This review aims to summarize and compare various tools used for assessing chemotherapy-induced peripheral neuropathy (CIPN).
Conducted comprehensive literature search following SANRA guidelines.
Identified measurement tools including clinician-based scales, patient-reported outcomes, and objective measures.
Extracted data and characteristics of tools from selected papers and appendices.
Identified 3 clinician-based grading scales for CIPN assessment.
Found 20 patient-reported outcome measures (PROMs) and 8 objective tools for measuring CIPN.
Most tools are validated for neuropathy, but few have established minimum clinically important differences (MCIDs) specific to CIPN.

Structured PICO

Population

Patients with chemotherapy-induced peripheral neuropathy (CIPN)

Intervention

CIPN assessment tools (clinician-based grading scales, patient-reported outcome measures, and objective measures)

Outcome

Characteristics of CIPN assessment tools including feasibility, minimum clinically important differences (MCIDs), validity, and reliability

A variety of clinician-based, patient-reported, and objective tools exist for assessing CIPN, but many lack validation and established MCIDs in CIPN-specific populations.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

Abstract Background Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of chemotherapy, affecting motor, sensory, and autonomic function. Accurate assessment is important during treatment, when CIPN may necessitate does reductions or discontinuation, and after treatment, as chronic CIPN can greatly impact quality of life and safety in cancer survivorship. Measurement tools can include subjective measures, including clinician-based grading scales or patient reported outcome measures (PROMs), and objective measures. This review aimed to summarize current CIPN assessment tools, highlighting characteristics such as feasibility, minimum clinically important differences (MCIDs), validity and reliability to allow for comparison and selection of tools by clinicians and researchers. Methods Following the Scale for the Assessment of Narrative Review Articles (SANRA) methodology guidelines, two investigators performed a comprehensive literature search using pre-defined search terms relating to CIPN measurement. Additional papers were identified through a search of prior systematic reviews and tracing back references from key articles. Data was extracted from source papers and any available appendices. Results We identified 3 clinician-based grading scales, 20 PROMs and 8 objective measurement tools. While the majority of tools have been validated for neuropathy, a minority of them have established MCIDs and validation in CIPN specific populations. Conclusions Tool selection should align with the specific needs of clinicians and researchers. Instruments that are valid, reliable, and assess multiple CIPN domains are recommended. Further research is needed to validate many of these tools in CIPN-specific populations and to determine their MCIDs.

Ask AI

Helpful

Bookmark

View Full Paper